When to Get the Shingles Vaccine
Adults aged 50 years and older should receive the recombinant zoster vaccine (RZV/Shingrix) as a 2-dose series, administered 2-6 months apart, regardless of prior shingles history. 1
Age-Based Recommendations
Standard Adult Population
- Age 50 and older: The recombinant zoster vaccine (RZV) is the preferred vaccine for all immunocompetent adults starting at age 50 1, 2
- Age 60 and older: If RZV is unavailable, the older live zoster vaccine (ZVL/Zostavax) may be used as an alternative, though RZV remains strongly preferred 1
The most recent 2020 ACIP guidelines represent a shift from older recommendations (2012-2014) that suggested waiting until age 60. The current standard is to begin vaccination at age 50, which provides earlier protection during the period when shingles risk begins to substantially increase 1, 3.
Immunocompromised Adults
Adults aged 19 years and older who are or will be immunocompromised should receive RZV regardless of age 3. This includes individuals with:
- HIV infection
- Hematologic malignancies (leukemia, lymphoma, multiple myeloma)
- Solid organ transplant recipients
- Hematopoietic stem cell transplant recipients
- Autoimmune diseases requiring immunosuppressive therapy
- Chronic renal failure
- Those receiving immunosuppressive medications (systemic corticosteroids, JAK inhibitors, combination therapies) 4, 3
Timing consideration: Ideally, administer the first dose at least 14 days before starting immunosuppressive treatment when possible 4. For immunocompromised patients, the interval between doses may be shortened to 1-2 months instead of the standard 2-6 months 4.
Dosing Schedule
- Dose 1: Administer at appropriate age (50+ for immunocompetent, 19+ for immunocompromised)
- Dose 2: Give 2-6 months after the first dose (minimum interval: 4 weeks; if given too soon, repeat the dose) 1
- Both doses are required for optimal protection
Special Circumstances
Prior Shingles History
Vaccinate regardless of whether the patient reports a previous episode of herpes zoster 5, 1
Prior Zostavax (ZVL) Vaccination
If previously received the older live vaccine (ZVL), administer RZV at least 2 months after ZVL 1
Pregnancy
- RZV: Consider delaying until after pregnancy if otherwise indicated
- ZVL: Contraindicated during pregnancy 1
Severe Immunocompromising Conditions
- RZV can be administered to most immunocompromised patients 3
- ZVL is contraindicated in severe immunodeficiency 1
- HIV patients with CD4 count <200 cells/μL: RZV may be considered, but ZVL is contraindicated 1
Common Pitfalls to Avoid
- Don't wait until age 60: The updated recommendation is age 50 for routine vaccination
- Don't skip immunocompromised younger adults: Those aged 19+ with immunocompromise qualify for vaccination
- Don't use the wrong vaccine in immunocompromised patients: Only RZV (not the live ZVL) should be used in immunocompromised individuals
- Don't forget the second dose: Both doses are necessary for optimal protection; the series is incomplete with only one dose
- Don't delay vaccination in patients about to start immunosuppressive therapy: Vaccinate at least 14 days before treatment initiation when feasible
Why This Matters for Morbidity and Mortality
Approximately one-third of the population will develop herpes zoster, with 10-18% developing postherpetic neuralgia—a chronic, debilitating pain syndrome lasting beyond 90 days 2. Immunocompromised individuals face even higher risks of both shingles and severe complications 2, 6. RZV demonstrates high efficacy in preventing shingles, postherpetic neuralgia, and other complications, with protection persisting for 10 years after vaccination 4. The vaccine has proven cost-effective and significantly reduces disease burden, particularly in high-risk populations 6.